Sage Journals: Discover world-class research

Open access

Research article

First published 2022-1

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

Enrique Alvarez, Kavita V. Nair, Stefan Sillau [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2023-4

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine

Sarah Conway, Shrishti Saxena, Clare Baecher-Allan [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2024

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials

Tobias Derfuss, Robert Bermel, Chien-Ju Lin [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2021

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2025-7

Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies

Emma C Tallantyre, Emily Jacob, Laura Davies [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2025-7

Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial

Naghmeh Abbasi Kasbi, Ali Rezaei, Reyhaneh Montazeri [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2025-4

Reporting on Adverse Clinical Events

Clin-Alert

Search results

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies

Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial

Reporting on Adverse Clinical Events